Shots:

• Kamada will commercialize Alvotech’s biosimilar portfolio consisting of 6 products in Israel- upon its Israeli Ministry of Health (IMOH) approval while Alvotech will remain responsible for development- manufacturing and supply of all products
• The collaboration leverages Kamada’s expertise and presence in the Israeli market and enables Kamada to benefit from the long-term growth potential of the emerging class of biosimilar drugs
• Alvotech’s biosimilar portfolio includes candidates targeting autoimmunity- oncology and- inflammatory conditions. If approved by IMOH- Kamada will launch PF708 (biosimilar- teriparatide) referencing Eli Lilly’s Forteo in 2020 with the anticipated launch of the remaining five products in 2023-2025

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Bio news